Studies performed in Asian populations report KRAS mutation prevalence varying from 37.9% (Japan) to 52.7% (China), whereas NRAS and BRAF mutations prevalence are closer with China reporting 3.4% and 4.5% while Japan referring 4.2% and 5.4%, respectively [8,38], nevertheless, population-based studies report up to 20% of CRC patients with BRAF mutations [39,40]. The gene discussed is NRAS; the disease is colorectal carcinoma.